NCIt definition : A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell
surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon
administration, daratumumab targets and binds to CD38 expressed on tumor cells. This
triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent
cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity
(CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab
depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived
suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on
various immune cells and hematologic malignancies.;
UNII : 4Z63YK6E0E;
CAS number : 945721-28-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 945721-28-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;